A generic alternative indicated for HIV. This formulation promotes interference with viral reverse transcriptase, supporting the suppression of viral progress.
Designed to alleviate HIV-1 infection severity by addressing viral replication to support immune system strength and mitigate disease progression in infected adults and children.
Mechanism of Action
Efavirenz binds to the reverse transcriptase enzyme of the HIV virus. By blocking this enzyme, the virus cannot convert its RNA into DNA, which effectively stops it from replicating and infecting new immune cells.
Route of Administration
Oral
Onset Time
Steady state in 1–2 weeks
Duration
24 hours
Contraindications
Concurrent use of midazolam, pimozide, or ergot derivatives, Severe liver impairment, Hypersensitivity to efavirenz
Severe Adverse Events
Severe psychiatric symptoms (Depression), Liver toxicity, Severe skin reactions, Convulsions, Fetal harm (1st trimester risk)
Information for Efavirenz is sourced from established medical standards and updated frequently. It is provided for general reference and should be confirmed with a healthcare professional before use.
